Losartan, Losartan/HCTZ recall manufactured by Torrent

September 23, 2019

On September 19, 2019, Torrent Pharmaceutical announced an expanded recall of specific lots of Losartan tablets (50mg and 100mg), and Losartan/hydrochlorothiazide tablets (50mg/12.5mg and 100mg/25mg) due to the detection of an unexpected impurity (NMBA) found in the active pharmaceutical ingredient.

Losartan Potassium Tablets, USP 50mg, lot # 4DU2E009, exp 12/31/2020, NDC 13668-409-10 Losartan Potassium Tablets, USP 100mg, lot# 4DU3E009, exp 12/31/2020, NDC 13668-115-90 Losartan Potassium Tablets, USP 100mg, lot # 4DU3D018, exp 02/28/2021, NDC 13668-115-10 Losartan Potassium / Hydrochlorothiazide Tablets, USP 50mg/12.5mg, lot# BEF7D051, exp 11/30/2020, NDC 13668-116-90 *Losartan Potassium / Hydrochlorothiazide Tablets, USP 100mg/25mg, lot # 4P04D007, exp 07/31/2020, NDC 13668-118-90

Additional information is available on the FDA's website:

https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/updated-torrent-pharmaceuticals-limited-expands-voluntary-nationwide-recall-losartan-potassium-0

Last updated: March 13, 2020

The information on this site is not intended to take the place of your doctor or other healthcare professionals. It is a resource to help you make the best decisions and get the most from the medical services available to you. A licensed physician should be consulted for diagnosis and treatment of all medical conditions.